VAN HERK INVESTMENTS B.V. ANNOUNCES 10.07% SHAREHOLDING IN ABLYNX
January 24 2017 - 1:00AM
REGULATED INFORMATION
GHENT, Belgium,
24 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today
announced, in accordance with Article 14 of the Belgian Law of 2
May 2007 regarding the publication of major shareholdings in
issuers whose securities are admitted to trading on a regulated
market (the "Transparency Law"), that it received a notification of
shareholdings from Van Herk Investments B.V.
The above shareholder notified
Ablynx that it has exceeded the 10% threshold on 19 January 2017
and now holds 6,148,362 Ablynx shares, representing 10.07% of the
current 61,076,074 outstanding Ablynx shares, an increase from a
former position of 5.40% (August 2016).
Van Herk Investments B.V. is
controlled by Mr. A. van Herk in accordance with Articles 5 and 7
of the Dutch Companies Code.
Full versions of all transparency
notifications are available on Ablynx website, under the section
Investors.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies®, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie, Boehringer Ingelheim,
Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo
Nordisk and Taisho Pharmaceuticals. The Company is headquartered in
Ghent, Belgium. More information can be found on
www.ablynx.com.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Marieke Vermeersch
Director IR & Corporate Communications
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media/analyst
relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: ablynx@fticonsulting.com
pdf format of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire